Last updated on September 2015

Autosomal Dominant Polycystic Kidney Disease


Brief description of study

Autosomal Dominant Polycystic Kidney Disease

Detailed Study Description

Otsuka Pharmaceuticals is studying an investigational drug called tolvaptan. It is approved in Japan, Canade & England for the treatment of autosomal dominant polycystic kidney disease. When take chronically, tolvaptan seems to slow the rate at which the kidney grows and also seems to slow the rate at which kidney function declines.

Clinical Study Identifier: TX141471

Contact Investigators or Research Sites near you

Start Over

Stephanie Hanzl

Northeast Clinical Research Center, LLC.
Bethlehem, PA USA
  Connect »